Stock · NEULANDLAB · Healthcare
NEULANDLAB share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for NEULAND LABORATORIES LIMITED, refreshed every end-of-day run. A systematic, data-only read on NEULAND LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads NEULANDLAB as constructive with a Crack Score of 93/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where NEULANDLAB stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
60/100Money flow
53/100Result pulse · Q4 FY26
0/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
Red flags
above 200DMA (not a confirmed short-side trend)
weak filed result (score 0.0)
Relative valuation
P/E (TTM)
66.6P/E vs sector
+1.3%Sector percentile
70PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for NEULANDLAB are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the NEULANDLAB chart, refreshed every end-of-day run.
The Crack Score, and how it is built93 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for NEULANDLAB, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on NEULANDLAB reads right now.
The editorial price read on NEULANDLAB is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on NEULANDLAB can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving NEULANDLAB.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why NEULANDLAB moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
NEULAND LABORATORIES LIMITED's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.
Result Pulse
0 / 100Revenue
Rs 776 crNet profit
Rs 213 crEPS (quarter)
Rs 165.76| Growth | YoY | QoQ |
|---|---|---|
| Revenue | n/a | n/a |
| Net profit | n/a | n/a |
| Net margin | n/a | |
Figures are the Q4 FY26 result for NEULAND LABORATORIES LIMITED, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
NEULAND LABORATORIES LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
NEULANDLAB official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 776 cr | Rs 165.76 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 440 cr | Rs 31.62 | n/a | 40/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 514 cr | Rs 75.49 | n/a | 68/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 293 cr | Rs 10.83 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 328 cr | Rs 21.67 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 398 cr | Rs 79.18 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 311 cr | Rs 25.60 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 440 cr | Rs 76.28 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 385 cr | Rs 52.66 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 393 cr | Rs 63.44 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 418 cr | Rs 69.56 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 363 cr | Rs 48.23 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 407 cr | Rs 65.90 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 269 cr | Rs 23.81 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 294 cr | Rs 29.97 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 221 cr | Rs 7.77 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 256 cr | Rs 17.01 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 236 cr | Rs 10.08 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 258 cr | Rs 15.88 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 201 cr | Rs 6.81 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 245 cr | Rs 13.48 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 245 cr | Rs 20.84 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 241 cr | Rs 16.71 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 205 cr | Rs 11.82 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 192 cr | Rs -7.25 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 204 cr | Rs 8.66 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 186 cr | Rs 6.77 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 181 cr | Rs 4.45 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Standalone, audited | Rs 173 cr | Rs 5.25 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Standalone, audited | Rs 171 cr | Rs 3.59 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Standalone, audited | Rs 169 cr | Rs 3.43 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Standalone, audited | Rs 154 cr | Rs 0.35 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
NEULAND LABORATORIES LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
2,023 crNet profit (TTM)
364 crEBIT (TTM)
513 crProfit before tax (TTM)
489 crNet margin (TTM)
18.0%Finance costs (TTM)
23.9 crBalance sheet, as filed 2026-03-31
Total assets
2,930 crShareholder equity
1,874 crTotal borrowings
197 crCash and equivalents
76.7 crInventory
510 crTrade receivables
541 crThe cash engine, latest filed year
Operating cash flow
347 crCapex
396 crFree cash flow
-49.4 crInvesting flow
424 crFinancing flow
21.0 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 2,023 cr | 364 cr | 1,874 cr | 197 cr | 347 cr |
| FY25 | 1,477 cr | 260 cr | 1,525 cr | 136 cr | 317 cr |
| FY24 | 1,559 cr | 300 cr | 1,283 cr | 82.5 cr | 261 cr |
| FY23 | 1,191 cr | 164 cr | 994 cr | 122 cr | 237 cr |
| FY22 | 951 cr | 63.8 cr | 841 cr | 231 cr | 58.6 cr |
| FY21 | 937 cr | 80.6 cr | 786 cr | 145 cr | n/a |
Every figure is parsed from NEULAND LABORATORIES LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record17 earnings calls
Every NEULANDLAB earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
NEULAND LABORATORIES LIMITED earnings calls on record
17 calls since 31 May 2022
Show 9 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from NEULAND LABORATORIES LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
NEULAND LABORATORIES LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100NEULAND LABORATORIES LIMITED Q4 FY26 earnings result: profit_acceleration
Event Heat is a dated net read of NEULAND LABORATORIES LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the NEULANDLAB chart. Not a substitute for a registered research note.
| Ticker | NEULANDLAB |
|---|---|
| Full name | NEULAND LABORATORIES LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE794A01010 |
| Market-cap band | ~24,242 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | NEULANDLAB |
Reference chartLevels in show
The daily frame the desk reads on NEULANDLAB.
FAQ11 reader questions · AEO-eligible
The line on NEULANDLAB, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the NEULANDLAB share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on NEULANDLAB. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for NEULANDLAB?
The BazaarBaazi Crack Score for NEULANDLAB is 93 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on NEULANDLAB?
Strike-level option inventory for NEULANDLAB is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is NEULANDLAB in and which peers does BazaarBaazi track?
NEULANDLAB sits in Healthcare (mid cap), indicative market cap ~24,242 cr (indicative), ISIN INE794A01010. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on NEULAND LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the NEULANDLAB view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on NEULANDLAB is bullish, published in Systematic Read on 21 Jul 2026.
Is NEULANDLAB a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, NEULAND LABORATORIES LIMITED sits in the Scanned tier with a setup score of 74/100 (technical 100, fundamental 60). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read NEULAND LABORATORIES LIMITED's earnings call transcripts?
BazaarBaazi indexes 17 NEULANDLAB earnings calls going back to 2022-05-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was NEULAND LABORATORIES LIMITED's Q4 FY26 net profit?
NEULAND LABORATORIES LIMITED reported a net profit of Rs 213 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.
What was NEULAND LABORATORIES LIMITED's Q4 FY26 revenue?
NEULAND LABORATORIES LIMITED reported revenue of Rs 776 cr for Q4 FY26. The figure is from the company's official NSE filing.
How does BazaarBaazi rate NEULAND LABORATORIES LIMITED's Q4 FY26 result?
BazaarBaazi gives NEULAND LABORATORIES LIMITED's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Neuland Laboratories Ltd announced recently?
The most recent official filing on record for Neuland Laboratories Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside NEULANDLAB, each a living view refreshed every end-of-day run.